PHIA Koninklijke Philips N.V.

Philips and MIT IMES develop enhanced critical care data set to give researchers and educators access to advance clinical understanding and AI in healthcare

Philips and MIT IMES develop enhanced critical care data set to give researchers and educators access to advance clinical understanding and AI in healthcare

April 18, 2023

Latest clinical data set of 200,000 patients from over 200 hospitals, includes pandemic data for a broader and dependable foundation for machine learning

Amsterdam, the Netherlands and Cambridge, MA, USA – (NYSE: PHG, AEX: PHIA), a health technology provider, today announced an expansion of its initiative with the at the Massachusetts Institute of Technology (MIT) to allow health care researchers access to a new critical care data set to help advance machine learning and artificial intelligence (AI) in healthcare. The updated eICU Collaborative Research Database (eICU-CRD) includes de-identified data of 200,000 critical care patients, including patients who were impacted by COVID-19. The broader and clinically dependable data set will support the development of solutions that improve patient care and clinical outcomes.

During the COVID-19 pandemic, eICU and critical care saw a dramatic increase of patients and unique challenges in the way that care was provided, prompting Philips and IMES to expand the original data set, first released in 2016. The new secure database includes de-identified and detailed clinical information such as vital signs, pharmacy and medication orders, laboratory results, diagnoses, and novel severity of illness scores. The dataset gives comprehensive insights on patient treatments, co-morbidities, readmissions, and clinical outcomes.

Researchers at Philips and the Laboratory of Computational Physiology within IMES will grant researchers around the world access to the data to help develop advanced algorithms and provide new insights on critical care. The Laboratory of Computational Physiology will continue to serve as the academic research hub for the initiative and will provide and maintain access, as well as help educate researchers on the database and offer a platform for collaboration. The database is available for medical research, to those who are credentialed, who take human subjects training, and who agree to a data use agreement.

“The database, which includes patient information from 2020 and 2021, now contains significant overlap with the Covid-19 pandemic, yielding valuable patient data for research,” said Leo Anthony Celi, principal research scientist and clinical research director at the Laboratory of Computational Physiology at IMES. “This updated database is a vital resource for education, including in many courses at institutions like Harvard, MIT and Stanford; and training, as well as low-resource institutions,” said Jesse D. Raffa, research scientist in the Lab for Computational Physiology at IMES.

The eICU-CRD is the only dataset containing detailed critical care data from over 200 hospitals across the U.S., representing many ‘real-world’ challenges for successful deployment of algorithms and models, which are often not readily apparent in single-center datasets. Unlike other organizations that do not share data or only share single source data sets, Philips shares its data with credentialled researchers to help advance AI for improving outcomes in human health. More than 3,000 users have used the original database with citations in over 660 published academic research papers, including in Nature, The New England Journal of Medicine and the Journal of the American Medical Association.

“This initiative demonstrates our commitment to advancing machine learning and AI efforts, by making eICU data available for global research initiatives,” said Shiv Gopalkrishnan, General Manager of EMR & Care Management at Philips. “This is how we can enhance patient care and improve clinical outcomes: liberating and connecting data across systems and applications with integrated devices, systems and informatics, which can inform research with patient insights that can help clinicians make the right decision at the right time for their patients.”

For further information, please contact:





Silvie Casanova

Philips North America

Tel.

E-mail:

Anna Hogrebe

Philips Global Press Office

Tel.:

E-mail:



Mindy Blodgett

MIT IMES

Tel.

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

About IMES

The Institute for Medical Engineering and Science (IMES) at the Massachusetts Institute of Technology (MIT) is an inclusive community of students, administrative staff, research staff, and faculty who research, work, educate, and learn, at the convergence of engineering, science, and medicine to transform human health for all. More about IMES can be found at . 

Attachment



EN
18/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

Oscar Rodriguez
  • Oscar Rodriguez

PHILIPS: RDOS. 4T’25 Y CAMBIO DE P.O. AL ALZA (ANÁLISIS BANCO SABADELL...

Rdos. 4T’25 vs 4T’24: Ventas: 5.097 M euros (+1,1% vs -0,9% BS(e) y -1,0% consenso); EBITA Aj.: 770 M euros (+13,4% vs +0,6% BS(e) y -1,0% consenso); BDI: 397 M euros (-333 M euros en 2024 vs 275 M euros BS(e) y 276 M euros consenso); Rdos. 2025 vs 2024: Ventas: 17.834 M euros (-1,0% vs -1,6% BS(e) y -1,6% consenso); EBITA Aj.: 2.195 M euros (+5,7% vs +1,5% BS(e) y +1,0% consenso); BDI: 897 M euros (-698 M euros en 2024 vs 775 M euros BS(e) y 776 M euros consenso).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch